Watch Ticker

Travere Therapeutics, Inc. Common Stock

Go to Travere Therapeutics, Inc. Common Stock Website

$16.68

0.72 (4.51%)

Live

Previous Close

$15.96

Day Range

$15.645 - $16.88

Previous Day Range

$15.42 - $16.2

Market Cap

$1.4 billion USD

Day Vol.

1.8 million

Previous Day Vol.

894134

Currency

USD

Primary Exchange

Nasdaq

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition. If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS.

Related tickers: TVTX.

Read Full Article

N/A - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics announced that it granted inducement equity grants covering 115,100 shares of its common stock to ten new employees, consisting of stock options and restricted stock units. These grants were made as inducements to the new employees to join the company.

Related tickers: TVTX.

Read Full Article

Trending Tickers

Please sign in to view